RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) announced that its board compensation committee granted inducement stock option and restricted stock unit awards to two new non-executive employees on February 9, 2026, in connection with their employment.
The company said the awards cover options for 33,504 shares of common stock and restricted stock units for 25,128 shares under its 2025 Employment Inducement Incentive Award Plan.
According to Mineralys, the stock options will vest over four years, with 25% of the shares vesting on the first anniversary of the February 9, 2026 vesting commencement date and the remainder vesting monthly thereafter, subject to continued employment.
The restricted stock units will also vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the vesting commencement date.
Mineralys said the awards were granted as a material inducement to the employees entering into employment with the company, in accordance with Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing treatments targeting hypertension and related conditions, including chronic kidney disease and obstructive sleep apnea. Its lead product candidate, lorundrostat, is an orally administered aldosterone synthase inhibitor.
The company is headquartered in Radnor.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.